A Massachusetts-based biotechnology company has agreed to pay $22.28
million to resolve allegations brought by whistle-blowers in Tampa and
Miami that it marketed an inappropriate use for a surgery medication,
U.S. government attorneys said.
Genzyme, a corporation known for its research into drugs for rare
genetic diseases, is paying the settlement in a lawsuit over Seprafilm, a
material it manufactures for use in the operating room.
http://www.tampabay.com/news/courts/civil/boston-biotech-firm-genzyme-agrees-to-pay-22-million-in-tampa/2158332
